NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

July 10, 2021

Study Completion Date

August 8, 2021

Conditions

Pulmonary EmbolismCOVID

Interventions

DRUG

TNKase

Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.

DRUG

Placebo

Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.

DRUG

Enoxaparin

All participants must also receive standard of care anticoagulation therapy.

Trial Locations (1)

Cedars-Sinai Medical Center, Los Angeles